Implementation of the Hospital Readmissions Reduction Program (HRRP) among fee-for-service Medicare beneficiaries discharged after heart failure (HF) hospitalizations was temporarily associated with a reduction in 30-day and 1-year readmissions, but an increase in 30-day and 1-year mortality. This according to an observational study of 115,245 fee-for-service Medicare beneficiaries (mean age 80.5 years, 54.6% women, 81.3% white, 9.7% black) that examined risk-adjusted 30-day and 1-year all-cause readmission and mortality rates. Researchers found:
- 30-day risk-adjusted readmission rate declined from 20.0% before the HRRP implementation to 18.4% in the HRRP penalties phase (HR after vs before implementation, 0.91).
- Conversely, the 30-day risk-adjusted mortality rate increased from 7.2% before the HRRP implementation to 8.6% in the HRRP penalties phase (HR after vs before implementation, 1.18).
- The 1-year risk-adjusted readmission and mortality rates followed a similar pattern as the 30-day outcomes.
Gupta A, Allen LA, Bhatt DL, et al. Association of the Hospital Readmissions Reduction Program Implementation with readmission and mortality outcomes in heart failure. [Published online ahead of print November 12, 2017]. JAMA Cardiol. doi:10.1001/jamacardio.2017.4265.
This Week's Must Reads
HCV Treatment for PWID at Syringe Program, Open Forum Infect Dis; ePub 2018 Mar 6; Eckhardt, et al
Analyzing HCV Treatment in Uninsured Patients, J Community Health; ePub 2018 Mar 6; Sims, et al
To Treat or Not to Treat Acute HCV?, Hepatology; 2018 Mar; Bethea, Chen, et al
Treating Patients with HCV/HIV Coinfection, Hepatology; 2018 Mar; Sikavi, Chen, et al
Liver Stiffness in HCV Patients on Antiviral Therapy, J Gastroenterol Hepatol; ePub 2018 Feb 1; Facciorusso, et al
Must Reads in Cardiology
Intensive BP Treatment & Subsequent CVD Risk, J Am Coll Cardiol; ePub 2018 Mar 7; Phillips, et al
Association of BMI with Lifetime Risk of CVD, JAMA Cardiol; ePub 2018 Feb 28; Khan, et al
Collaborative Care vs Usual Care in Heart Failure, JAMA Intern Med; ePub 2018 Feb 26; Bekelman, et al
Hypertension & Antihypertensive Medication Use, MMWR; 2018 Feb 23; Fang, Gillespie, et al
Aspirin vs Rivaroxaban for VTE Prophylaxis, N Engl J Med; 2018 Feb 22; Anderson, et al